Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Safety and tolerability were observed to be consistent with prior batoclimab studies. Immunovant plans to initiate potentially registrational studies in both MG and CIDP with lead asset IMVT-1402 and ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical ...

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

Safety and tolerability were observed to be consistent with prior batoclimab studies. Path Forward in MG and CIDP Immunovant plans to initiate potentially registrational studies in both MG and ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Batoclimab met the primary endpoint in a Phase 3 MG study, showing up to a 5.6-point MG-ADL improvement with 74% mean IgG reduction. Immunovant will not seek approval for batoclimab in MG or CIDP ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...